Loading…

AstraZeneca PLCAZN.LCompetitor analysis, valuation and peers

United Kingdom · GBP·Health Care›Pharmaceuticals: Major

British-Swedish pharmaceutical major focused on oncology, cardiovascular/metabolic, respiratory/immunology and rare-disease medicines.

Momentum strong 70
Mkt cap
$278B
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$416M
20-day average traded
Fwd P/E
17.6×
forward earnings
ROIC−WACC
+4.4 pp
WACC 9.4%
Hurdle
-1 pp
Req g minus delivered
Official | Implied
A+ / AA+
agencies · bond market
Next earnings
85 days
11 Feb 2027
Close · GBP£13,646
1D-1.1%
1W-1.8%
1M+8.2%
3M+12.9%
6M-1.9%
YTD-1.0%
1Y+0.4%
ATR %2.2%
52w lowhigh13.2% off high

What AstraZeneca does

British-Swedish pharmaceutical major focused on oncology, cardiovascular/metabolic, respiratory/immunology and rare-disease medicines.

Earns by selling patent-protected prescription medicines through hospitals and health systems, with oncology the largest area and emerging markets, notably China, an important region. It bought Alexion in 2021 to add its rare-disease business.

Products and services

  • Oncology
  • Cardiovascular, Renal & Metabolism
  • Respiratory & Immunology
  • Rare Disease (Alexion)

Customers

  • Hospitals/oncologists
  • Health systems/payers globally

Where it sits in the supply chain

  • Health Care
  • Biopharmaceuticals
  • Drug discovery, development…

What could go right

  • New oncology drug launches/label expansions
  • Emerging-market volume growth

What could go wrong

  • Patent expiries on older blockbusters
  • Drug-pricing policy (US IRA)

Moat: wide (IP / patents, scale). Broad patent-protected oncology and biologics portfolio with a large global sales/trial infrastructure.

Headquarters: Cambridge, UK · Founded: 1999 · Employees: 96,100

Named competitors

AstraZeneca at a glance

Size AstraZeneca (AZN.L) is a United Kingdom Health Care company (Pharmaceuticals: Major) with a market value of $278B, the 2nd largest of 355 United Kingdom companies the cockpit tracks. Shares closed at £13,646 on 18 Nov 2026.

Performance Over six months the shares fell 1.9%, against +16.5% for the median peer and +0.1% for the United Kingdom market (cap-weighted) — 4th lowest of 16 in its peer set.

Growth Revenue grew 4.5% over the last twelve months (peer median +5.7%); the operating margin is 23.3% (peer median 30.4%).

Valuation It trades at 17.6× forward earnings against a peer median of 17.4× (7th most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -1 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 4.4 points above its cost of capital (9.4% WACC).

Credit AstraZeneca has 12 bonds outstanding ($8.79B), rated A+ by the agencies and trading like AA+ at a weighted spread of 61 bp.

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 115AZN.L 98
Six months, rebased to 100: AstraZeneca against the median of its 15 peers (local-currency closes).

AstraZeneca financials

Reported figures in GBP; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue£46.5B£44.6B£42.3B£36.9B£36.0B
Revenue growth—+5%+15%+2%—
Gross profit£34.5B£33.3B£31.7B£27.3B£22.8B
EBITDA£15.6B£14.8B£14.0B£11.5B£8.37B
Net income£8.22B£7.76B£5.51B£4.79B£2.67B
Free cash flow£7.78B£9.14B£8.04B£7.46B£7.13B
Capital expenditure£5.31B£4.48B£3.59B£3.04B£2.09B
Total debt£25.7B£22.0B£24.2B£22.5B£24.3B

Quarterly statements and history in the cockpit →

AstraZeneca competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%0%+10%NOVNMRKRONOVO-BPFEABBVVRTXBMYSANGSKREGN4519MRK4502AZN.L6-month return →1-month return →
Up and to the right = strong over both horizons. AstraZeneca is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×NOVNMRKRONOVO-BPFEABBVVRTXBMYJNJSANGSKREGN4519MRK4502AZN.LRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. AstraZeneca is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%-10%0%10%20%NOVNMRKRONOVO-BPFEABBVVRTXBMYJNJSANGSKREGN4519MRK4502AZN.LGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. AstraZeneca is the large dot.

AstraZeneca competitors and peer comparison

Head to head with its named competitors (AZN.L vs PFE vs MRK vs RO.SW)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
AstraZeneca AZN.L$278B-2%+5%23%17.6×14.4%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%
Merck & MRK$340B+23%+5%18%16.4×8.3%
Roche RO.SW$381B+21%-1%31%19.9×1.7%
Novartis NOVN.SW$285B+11%-4%30%17.5×1.6%
GSK GSK.L$97.9B-3%+4%25%10.4×-0.1%

How AstraZeneca compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

AstraZeneca against its 15 peers (data as of 18 Nov 2026)
MeasureAZN.LPeer medianRank in peer set
1-month return+8.2%+3.9%5th highest of 16
6-month return-1.9%+16.5%4th lowest of 16
Distance from 52-week high-13.2%-5.7%4th lowest of 16
Revenue growth (TTM)+4.5%+5.7%7th lowest of 16
Operating margin23.3%30.4%4th lowest of 16
Forward P/E17.6×17.4×7th most expensive of 16
Growth the price implies (Req g, 7 yrs)14.4%1.6%most demanding of 16
Growth delivered (Del g)+15.7%+6.0%2nd highest of 16
Hurdle (Req g minus delivered)-1.3 pp-4.8 pp7th most demanding of 16
ROIC minus cost of capital+4.4 pp+10.5 pp5th lowest of 16
EV / EBITDA14.8×14.9×8th cheapest of 16
Net debt / EBITDA1.2×1.2×8th most indebted of 16
Bond spread61 bp68 bp4th tightest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
AstraZeneca AZN.LUnited Kingdom$278B-2%+5%23%17.6×14.4%+15.7%
Novartis NOVN.SWSwitzerland$285B+11%-4%30%17.5×1.6%-0.2%
Merck & MRKUnited States$340B+23%+5%18%16.4×8.3%+9.3%
Roche RO.SWSwitzerland$381B+21%-1%31%19.9×1.7%+1.1%
Novo Nordisk A/S NOVO-B.CODenmark$177B-6%+6%48%11.8×-0.5%+19.5%
Pfizer PFEUnited States$160B+9%+1%26%9.9×-4.3%+8.5%
AbbVie ABBVUnited States$506B+35%+11%36%18.1×-0.1%+6.0%
Vertex Pharmaceuticals VRTXUnited States$136B+25%+11%35%28.5×6.2%+14.2%
Bristol Myers Squibb BMYUnited States$122B+3%+4%33%9.2×-13.1%+2.5%
Johnson & Johnson JNJUnited States$656B+20%+8%26%24.2×3.7%+2.7%
Sanofi SAN.PAFrance$114B+13%+15%27%9.7×-4.8%+3.9%
GSK GSK.LUnited Kingdom$97.9B-3%+4%25%10.4×-0.1%-0.9%
Regeneron Pharmaceuticals REGNUnited States$97.8B+46%+19%30%11.8×-1.1%+11.0%
Chugai Pharmaceutical 4519.TJapan$75.2B-8%+17%50%23.7×5.0%+9.8%
Merck KGaA MRK.DEGermany$71.3B+16%+1%19%17.4×7.4%+3.8%
Takeda Pharmaceutical 4502.TJapan$69.8B+30%+6%18%51.0×3.7%+7.1%

AstraZeneca bonds and credit

AstraZeneca has 12 bonds outstanding with $8.79B face value. The agencies rate it A+; its bonds trade like AA+. Weighted yield 4.01%, a spread of 61 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are AstraZeneca's main competitors?
Named competitors: Pfizer (PFE), Merck & Co (MRK), Roche (RO.SW), Novartis (NOVN.SW), GSK (GSK.L). The cockpit's measured peer set (industry) also includes Novartis (NOVN.SW), Merck & (MRK), Roche (RO.SW), Novo Nordisk A/S (NOVO-B.CO), Pfizer (PFE), AbbVie (ABBV).
Is AstraZeneca expensive compared with its peers?
On forward p/e it trades at 17.6× against a peer median of 17.4×, 7th most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -1 pp: the price already allows for a slowdown.
How has AstraZeneca stock performed?
Over six months to 18 Nov 2026 the shares returned -1.9% against +16.5% for the median peer; over one year +0.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.